Who are Gemcitabine plus Abraxane's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemcitabine + Nab-paclitaxel, Gemcitabine, Docetaxel, Gemcitabine combined with docetaxel, Gemcitabine combined with nab-paclitaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-plus-abraxane.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Gemcitabine plus Abraxane — Competitive Intelligence Brief

Gemcitabine plus Abraxane (Gemcitabine plus Abraxane) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (nucleoside analog + taxane). Area: Oncology.

phase 3 Chemotherapy combination (nucleoside analog + taxane) DNA synthesis (gemcitabine); tubulin/microtubules (paclitaxel) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine plus Abraxane (Gemcitabine plus Abraxane) — ERYtech Pharma. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Abraxane (paclitaxel albumin-bound) stabilizes microtubules to prevent cell division, together providing synergistic cytotoxic effects against cancer cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gemcitabine plus Abraxane TARGET	Gemcitabine plus Abraxane	ERYtech Pharma	phase 3	Chemotherapy combination (nucleoside analog + taxane)	DNA synthesis (gemcitabine); tubulin/microtubules (paclitaxel)
Gemcitabine + Nab-paclitaxel	Gemcitabine + Nab-paclitaxel	Verastem, Inc.	phase 3	Chemotherapy combination (nucleoside analog + taxane)
Gemcitabine, Docetaxel	Gemcitabine, Docetaxel	Central European Cooperative Oncology Group	phase 3	Chemotherapy combination (nucleoside analog + taxane)	DNA synthesis (gemcitabine); microtubule stabilization (docetaxel)
Gemcitabine combined with docetaxel	Gemcitabine combined with docetaxel	Hansoh BioMedical R&D Company	phase 3	Chemotherapy combination (nucleoside analog + taxane)	Ribonucleotide reductase (gemcitabine); β-tubulin/microtubules (docetaxel)
Gemcitabine combined with nab-paclitaxel	Gemcitabine combined with nab-paclitaxel	Pancreatic Cancer Action Network	phase 3	Chemotherapy combination (nucleoside analog + taxane)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (nucleoside analog + taxane) class)

Central European Cooperative Oncology Group · 1 drug in this class
ERYtech Pharma · 1 drug in this class
Hansoh BioMedical R&D Company · 1 drug in this class
Pancreatic Cancer Action Network · 1 drug in this class
Verastem, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine plus Abraxane — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-plus-abraxane. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab